Cellectar Biosciences, Inc. Contracts & Agreements

Form of Tranche A Warrant (Filed With SEC on September 8, 2023)

Form of Tranche B Warrant (Filed With SEC on September 8, 2023)

Form of Securities Purchase Agreement, dated September 5, 2023, by and among the Company and the purchasers named therein (Filed With SEC on September 8, 2023)

Cellectar Biosciences, Inc. 2021 Stock Incentive Plan, as Amended (Filed With SEC on June 29, 2023)

Description of Securities Registered under Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2023)

Form of First Amendment of Lease, dated December 30, 2022 (Filed With SEC on March 9, 2023)

Form of Indemnification Agreement (Filed With SEC on December 2, 2022)

Placement Agency Agreement, dated as of October 20, 2022, by and between Cellectar Biosciences, Inc. and Oppenheimer & Co. Inc (Filed With SEC on October 25, 2022)

Form of Common Warrant (Filed With SEC on October 25, 2022)

Form of Pre-Funded Warrant (Filed With SEC on October 25, 2022)

Form of Hybrid Securities Purchase Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein (Filed With SEC on October 25, 2022)

Form of PIPE Securities Purchase Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein (Filed With SEC on October 25, 2022)

Form of Registration Rights Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein (Filed With SEC on October 25, 2022)

Amendment 1 to the 2021 Stock Incentive Plan (Filed With SEC on June 27, 2022)

Description of Securities Registered under Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on May 10, 2022)

Employment Agreement between the Company and Chad Kolean, dated February 23, 2022 (Filed With SEC on February 25, 2022)

2021 Stock Incentive Plan (Filed With SEC on June 24, 2021)

Description of Securities Registered under Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2021)

Form of Underwriting Agreement (Filed With SEC on December 28, 2020)

Form of Series D Preferred Stock Certificate (Filed With SEC on December 28, 2020)

Form of Securities Purchase Agreement (Filed With SEC on December 28, 2020)

Form of Registration Rights Agreement (Filed With SEC on December 28, 2020)

Equity Distribution Agreement between Cellectar Biosciences, Inc. and Oppenheimer & Co. Inc., dated August 11, 2020 (Filed With SEC on August 11, 2020)

Employment Agreement between the Company and John Friend dated July 1, 2020 (Filed With SEC on July 1, 2020)

Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on June 25, 2020)

Form of Warrant Agency Agreement (Filed With SEC on June 5, 2020)

Form of Underwriting Agreement (Filed With SEC on May 20, 2020)

Form of Series H Warrant (Filed With SEC on May 20, 2020)

Form of Pre-Funded Warrant (Filed With SEC on May 20, 2020)

Description of Securities Registered under Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2020)

Stock Option Agreement with Dov Elefant (Filed With SEC on March 9, 2020)

Stock Option Agreement with Igor Grachev (Filed With SEC on March 9, 2020)

Amendment to Amended and Restated Employment Agreement between the Company and Jarrod Longcor, dated November 10, 2019 (Filed With SEC on November 12, 2019)

Employment Agreement between the Company and Dov Elefant dated August 15, 2019 (Filed With SEC on August 15, 2019)

Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on June 14, 2019)

Placement Agency Agreement dated as of May 16, 2019, by and between Cellectar Biosciences, Inc. and Roth Capital Partners, LLC (Filed With SEC on May 20, 2019)

Form of Series F Common Stock Purchase Warrant (Filed With SEC on May 20, 2019)

Form of Series G Common Stock Purchase Warrant (Filed With SEC on May 20, 2019)

Securities Purchase Agreement, dated as of May 16, 2019, by and among Cellectar Biosciences, Inc. and the Purchasers (Filed With SEC on May 20, 2019)

Private Placement Securities Purchase Agreement, dated as of May 16, 2019, by and among Cellectar Biosciences, Inc. and the Purchasers (Filed With SEC on May 20, 2019)

Registration Rights Agreement, dated as of May 16, 2019, by and among Cellectar Biosciences, Inc. and the Purchasers (Filed With SEC on May 20, 2019)

Amended and Restated Employment Agreement between the Company and James Caruso, dated April 15, 2019 (Filed With SEC on April 19, 2019)

Amended and Restated Employment Agreement between the Company and Jarrod Longcor, dated April 15, 2019 (Filed With SEC on April 19, 2019)

Form of Non-Statutory Stock Option (Definitive/Contingent Employees) (Filed With SEC on November 13, 2018)

Form of Non-Statutory Stock Option (Definitive/Contingent Directors) (Filed With SEC on November 13, 2018)

Employment Agreement between the Company and Brian Posner dated November 9, 2018 (Filed With SEC on November 13, 2018)

Form of Underwriting Agreement (Filed With SEC on July 18, 2018)

Form of Series E Common Stock Purchase Warrant (Filed With SEC on July 18, 2018)

Form of Series C Preferred Stock Certificate (Filed With SEC on July 18, 2018)

Form of Warrant Agency Agreement (Filed With SEC on July 18, 2018)

Agreement of Lease between the Company and KBS II 100-200 CAMPUS DRIVE, LLC dated June 4, 2018 (Filed With SEC on July 18, 2018)

Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on June 1, 2018)

Offer Letter between the Company and Brian Posner dated April 1, 2018 (Filed With SEC on April 4, 2018)

Master Services Agreement for Clinical Research and Related Services between the Company and INC Research, LLC dated October 6, 2016 (Filed With SEC on March 21, 2018)

Employment Agreement between the Company and Jarrod Longcor dated July 14, 2016 (Filed With SEC on November 9, 2017)

Employment Agreement between the Company and John E. Friend dated March 27, 2017 (Filed With SEC on November 9, 2017)

Placement Agency Agreement dated as of October 10, 2017, by and between Cellectar Biosciences, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on October 11, 2017)

Form of Series D Common Stock Purchase Warrant (Filed With SEC on October 11, 2017)

Form of Series B Preferred Stock certificate (Filed With SEC on October 11, 2017)

Securities Purchase Agreement, dated as of October 10, 2017, by and among Cellectar Biosciences, Inc. Inc. and the Purchasers (Filed With SEC on October 11, 2017)

Registration Rights Agreement, dated as of October 10, 2017, by and among Cellectar Biosciences, Inc. Inc. and the Purchasers (Filed With SEC on October 11, 2017)

RESTRICTED COMMON STOCK Granted by Cellectar Biosciences, Inc. (the“Company”) Under the 2015 Stock Incentive Plan (Filed With SEC on August 14, 2017)

Cellectar Biosciences, Inc. AMENDED AND RESTATED 2015 STOCK INCENTIVEPLAN (Filed With SEC on June 1, 2017)

_________ SHARESof Common StOCK _________ SHARESOF SERIES A CONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO______ SHARES OF COMMON STOCK) and __________SERIES C WARRANTS... (Filed With SEC on November 18, 2016)

Incorporated under the laws of the Stateof Delaware, June 24, 1996 (Filed With SEC on November 18, 2016)

SERIES C-2016 COMMON STOCK PURCHASE WARRANT cellectarbiosciences, inc. (Filed With SEC on November 18, 2016)

Cellectar Biosciences, Inc. and American Stock Transfer & Trust Company,LLC, as Warrant Agent (Filed With SEC on November 18, 2016)

____________ SHARES ofCommon Stock ____________ PRE-FUNDEDWarrants and ____________ WARRANTS(EXERCISABLE FOR _____SHARES) CELLECTAR BIOSCIENCES, INC. UNDERWRITING AGREEMENT (Filed With SEC on April 14, 2016)

SERIES A-2016 COMMON STOCK PURCHASE WARRANT cellectarbiosciences, inc. (Filed With SEC on April 14, 2016)

SERIES B-2016 PRE-FUNDED COMMON STOCKPURCHASE WARRANT cellectarbiosciences, inc. (Filed With SEC on April 14, 2016)

Cellectar Biosciences, Inc. and American Stock Transfer & Trust Company,LLC, as Warrant Agent (Filed With SEC on April 14, 2016)

[SIGNATURES ON THE FOLLOWINGPAGE] (Filed With SEC on April 14, 2016)

PLACEMENTAGENCY AGREEMENT (Filed With SEC on September 30, 2015)

SERIES B PREFUNDED COMMON STOCK PURCHASEWARRANT cellectarbiosciences, inc. (Filed With SEC on September 30, 2015)

SERIES ACOMMON STOCK PURCHASE WARRANT cellectarbiosciences, inc. (Filed With SEC on September 30, 2015)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on September 30, 2015)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on September 30, 2015)

Cellectar Biosciences, Inc. 2015 STOCK INCENTIVE PLAN (Filed With SEC on August 12, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on August 12, 2015)

NON-STATUTORY STOCK OPTION Granted by Cellectar Biosciences, Inc.(the “Company”) Under the 2015 Stock Incentive Plan (Filed With SEC on August 12, 2015)

NOTE PURCHASE AND SECURITY AGREEMENT (Filed With SEC on August 4, 2014)

8%SECURED PROMISSORY NOTE DUE[60 days from date of issue], 2014 (Filed With SEC on August 4, 2014)

CONSENT AGREEMENT (Filed With SEC on August 4, 2014)

UNDERWRITINGAGREEMENT between CELLECTARBIOSCIENCES, INC. and AEGIS CAPITALCORP., as Representativeof the Several Underwriters (Filed With SEC on July 7, 2014)

WARRANT AGREEMENT between CELLECTAR BIOSCIENCES, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY,LLC, AS WARRANT AGENT ________________________, 2014 (Filed With SEC on July 7, 2014)

8%CONVERTIBLE DEBENTURE DUEFebruary __, 2016 (Filed With SEC on February 10, 2014)

COMMON STOCK PURCHASE WARRANT novelostherapeutics, inc. (Filed With SEC on February 10, 2014)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on February 10, 2014)

Novelos Therapeutics, Inc. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN (Filed With SEC on December 18, 2013)

THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 13, 2013)

EXECUTIVERETENTION AGREEMENT (Filed With SEC on November 13, 2013)

CONSULTING AGREEMENT (Filed With SEC on November 13, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on November 13, 2013)

WAIVER AGREEMENT (Filed With SEC on October 11, 2013)

CLASS ___ COMMON STOCK PURCHASE WARRANT (Filed With SEC on February 14, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on February 14, 2013)

COMMON STOCKPURCHASE WARRANT __________ (Filed With SEC on January 31, 2013)

CLASS ___ COMMON STOCK PURCHASE WARRANT (Filed With SEC on November 20, 2012)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on November 20, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 6, 2012)

Novelos Therapeutics, Inc. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN (Filed With SEC on October 26, 2012)

AMENDMENT TO CLASS B COMMON STOCK PURCHASEWARRANT NOVELOS THERAPEUTICS, INC. (Filed With SEC on September 12, 2012)

CLASS ___ COMMON STOCK PURCHASE WARRANT __________ (Filed With SEC on June 11, 2012)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on June 11, 2012)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on June 6, 2012)

COMMON STOCK PURCHASE WARRANT __________ (Filed With SEC on May 14, 2012)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 14, 2012)

AMENDMENT AGREEMENT (Filed With SEC on May 14, 2012)

Rodman & Renshaw,LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212356 0500 Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on April 9, 2012)

UNDERWRITING AGREEMENT between NOVELOS THERAPEUTICS, INC. and RODMAN & RENSHAW, LLC as Underwriter NOVELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on December 7, 2011)

UNDERWRITING AGREEMENT between NOVELOS THERAPEUTICS INC. and RODMAN & RENSHAW, LLC as Underwriter (Filed With SEC on November 9, 2011)

COMMON STOCK PURCHASE WARRANT NOVELOS THERAPEUTICS, INC. (Filed With SEC on November 9, 2011)

LICENSE AGREEMENT MICHIGAN FILE 290 and 1225 (Filed With SEC on July 1, 2011)

LEASE (Filed With SEC on July 1, 2011)

LOAN AGREEMENT BETWEEN THE WISCONSIN DEPARTMENT OF COMMERCE AND CELLECTAR, INC. (Filed With SEC on July 1, 2011)

GENERAL BUSINESS SECURITY AGREEMENT (Filed With SEC on July 1, 2011)

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on June 1, 2011)

Novelos Therapeutics, Inc. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN (Filed With SEC on May 23, 2011)

AGREEMENT AND PLAN OF MERGER DATED AS OF April 8, 2011 BY AND AMONG NOVELOS THERAPEUTICS, INC., CELL ACQUISITION CORP., AND CELLECTAR, INC. TABLE OF CONTENTS (Filed With SEC on April 11, 2011)

CERTIFICATE OF ELIMINATION OF SERIES C 8% CUMULATIVE CONVERTIBLE PREFERRED STOCK OF NOVELOS THERAPEUTICS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the... (Filed With SEC on April 11, 2011)

CERTIFICATE OF ELIMINATION OF SERIES E CONVERTIBLE PREFERRED STOCK OF NOVELOS THERAPEUTICS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of... (Filed With SEC on April 11, 2011)

COMMON STOCK PURCHASE WARRANT NOVELOS THERAPEUTICS, INC. (Filed With SEC on April 11, 2011)

NOVELOSTHERAPEUTICS, INC. EXCHANGEAGREEMENT (Filed With SEC on November 30, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 22, 2010)

AMENDEDMENTTO CONSENT AND WAIVER OFHOLDERS OF SERIES C CONVERTIBLE PREFERRED STOCK AND SERIESE CONVERTIBLE PREFERRED STOCK OFNOVELOS THERAPEUTICS, INC. JULY21, 2010 (Filed With SEC on July 22, 2010)

COMMONSTOCK PURCHASE WARRANT NOVELOSTHERAPEUTICS, INC. (Filed With SEC on July 7, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 7, 2010)

WRITTENCONSENT AND WAIVER OFHOLDERS OF SERIES C CONVERTIBLE PREFERRED STOCK AND SERIESE CONVERTIBLE PREFERRED STOCK OFNOVELOS THERAPEUTICS, INC. (Filed With SEC on July 7, 2010)

NOVELOSTHERAPEUTICS, INC. FORMOF WARRANT TO PURCHASE [] SHARES OF COMMONSTOCK, PAR VALUE $0.00001 PER SHARE (Filed With SEC on July 7, 2010)

(A) As compensation for the services provided by Rodman hereunder, the Company agrees to pay to Rodman a cash fee payable immediately upon the closing of the Placement equal to 8%... (Filed With SEC on June 25, 2010)

EXECUTIVERETENTION AGREEMENT (Filed With SEC on May 17, 2010)

Descriptionof Bonus Plan adopted on December8, 2009 (Filed With SEC on January 26, 2010)

CONSENT AND AMENDMENTAGREEMENT (Filed With SEC on January 26, 2010)

NovelosTherapeutics, Inc. 2006Stock Incentive Plan (asAmended November 3, 2009) (Filed With SEC on December 7, 2009)

SECURITIES PURCHASEAGREEMENT (Filed With SEC on September 15, 2009)

REGISTRATION RIGHTSAGREEMENT (Filed With SEC on September 15, 2009)

NOVELOSTHERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE1,856,062 SHARESOF COMMONSTOCK, PAR VALUE $0.00001 PER SHARE (Filed With SEC on September 15, 2009)

LP CloverLimited Par LaVille Place 14Par-La-Ville Road P.O. BoxHM 2332 HamiltonHM JX, Bermuda (Filed With SEC on September 15, 2009)

MundipharmaInternational Corporation Limited Par LaVille Place 14Par-La-Ville Road P.O. BoxHM 2332 HamiltonHM JX, Bermuda (Filed With SEC on September 15, 2009)

EXCHANGEAGREEMENT (Filed With SEC on August 26, 2009)

COLLABORATIONAGREEMENT byand between NOVELOSTHERAPEUTICS, INC. (aDelaware corporation) and MUNDIPHARMAINTERNATIONAL CORPORATION LIMITED (aBermuda limited company) February11, 2009 (Filed With SEC on March 30, 2009)

CERTIFICATEOF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES ECONVERTIBLE PREFERRED STOCK OF NOVELOSTHERAPEUTICS, INC. (Pursuantto Section 151 of the DelawareGeneral Corporation... (Filed With SEC on February 18, 2009)

NOVELOSTHERAPEUTICS, INC. WARRANTTO PURCHASE 9,230,769 SHARES OF COMMONSTOCK, PAR VALUE $0.00001 PER SHARE (Filed With SEC on February 18, 2009)

CERTIFICATEOF ELIMINATION (Filed With SEC on February 18, 2009)

SECURITIES PURCHASEAGREEMENT (Filed With SEC on February 18, 2009)

REGISTRATION RIGHTSAGREEMENT (Filed With SEC on February 18, 2009)

NOVELOSTHERAPEUTICS, INC. SERIESD PREFERRED STOCK CONSENTAND AGREEMENT TO EXCHANGE (Filed With SEC on February 18, 2009)

WARRANTAMENDMENT AGREEMENT (Filed With SEC on February 18, 2009)

AMENDMENTNO. 2 TO REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on February 18, 2009)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 18, 2008)

CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES D CONVERTIBLE PREFERRED STOCK OF NOVELOS THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General... (Filed With SEC on April 14, 2008)

CERTIFICATE OF ELIMINATION OF SERIES A 8% CUMULATIVE CONVERTIBLE PREFERRED STOCK OF NOVELOS THERAPEUTICS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the... (Filed With SEC on April 14, 2008)

NOVELOS THERAPEUTICS, INC. WARRANT TO PURCHASE [_____________] SHARES OF COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Filed With SEC on April 14, 2008)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 14, 2008)

AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 14, 2008)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 14, 2008)

AMENDMENT TO REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 14, 2008)

WARRANT AMENDMENT AGREEMENT (Filed With SEC on April 14, 2008)

NOVELOS THERAPEUTICS ELECTS DR. STEPHEN HILL TO SERVE AS CHAIRMAN OF BOARD OF DIRECTORS (Filed With SEC on September 19, 2007)

NOVELOS THERAPEUTICS APPOINTS DR. JAMES MANUSO TO BOARD OF DIRECTORS (Filed With SEC on August 15, 2007)

Form of Incentive Stock Option under Novelos Therapeutics, Inc.s 2006 Stock Incentive Plan (Filed With SEC on December 15, 2006)

Form of Non-Statutory Stock Option under Novelos Therapeutics, Inc.s 2006 Stock Incentive Plan (Filed With SEC on December 15, 2006)

Form of Non-Statutory Director Stock Option under Novelos Therapeutics, Inc.s 2006 Stock Incentive Plan (Filed With SEC on December 15, 2006)

Category

Industry

Companies

Contracts

Cellectar Biosciences, Inc. Contracts & Agreements